Don’t be lured into the Bear Trap no matter how nice the honey tastes’.

Published 16-APR-2020 10:57 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Don’t be lured into the ‘Bear Market Trap’ and perceived honey pot of gains to be had just because the market has risen like a soufflé in the past few weeks.

The ill fated RMS Titanic after it hit the iceberg on 14 April 1912 did this too, as the stern of the ship rose one last time before it unceremoniously followed the bow down to the seabed of the Atlantic Ocean to its final resting place.

Unlike the Titanic, the Aussie sharemarket will rise again to meet another day and eventually get back to its all time high, but not before we reach the final low point in the current ‘Bear Market Cycle’.

Read: Sharemarket Delivers Another Bear Market 'Dead Cat Bounce'

Remember to ‘keep your heads whilst all around you lose theirs’.

The Aussie sharemarket is in the middle of a brief bear market rally mirroring the gains made back in October 2008 before the GFC pulled shares down a further 25% before we finally reached the bottom of the market in March 2009. In our case, and in the context of today, expect that bottom and buy signal to be reached sometime by year end 2020 or early 2021.

The downward pressure from low inflation and a near-term recession stand to make the Coronavirus virus induced profit slump deeper than past declines.

The unprecedented and massive Government stimulus packages will help, but will likely not be enough to prevent a massive slump in company’s earnings in the months ahead as we deal with an economy in shutdown and people and consumers in lockdown.

Many top 200 Aussie companies will not be able to maintain their dividends and many have to drop them in the light of the Coronavirus induced slump in earnings. Earnings, earnings, earnings is always the key driver of the sharemarket sending it to higher levels and nobody wants to see company’s cut their dividend.

The Australian sharemarket have technically returned to Bull market territory temporarily in recent days (although it has dipped slightly today), however the uptick will see a series of ‘dead cat’ market induced bounces. These will be a precursor to much deeper lows ahead of us as the full impact of a declining economy heading into a COVID-19 induced recession fully kicks in and delivers more bad news and company profit declines.

Despite all the doom and gloom, there is always a silver lining in the sharemarket

The good news is that in the months ahead, the market should produce the ‘best buying opportunity’ not seen since March 2009 when the index reached 3,109.

The recent gains we have just witnessed over the past week followed nearly two months of sharp selling amid fears of a coronavirus fuelled recession. That market trajectory and pattern closely matches past trends.

The danger is that at this moment in the cycle, many novice or inexperienced investors will be poised to re-enter the market only to be crushed as history suggests is normal.

Many investors need to keep their fuel dry and in the tank for future selective buying opportunities in dips in the market.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X